AR064659A1 - Nanoemulsion - Google Patents

Nanoemulsion

Info

Publication number
AR064659A1
AR064659A1 ARP070105827A ARP070105827A AR064659A1 AR 064659 A1 AR064659 A1 AR 064659A1 AR P070105827 A ARP070105827 A AR P070105827A AR P070105827 A ARP070105827 A AR P070105827A AR 064659 A1 AR064659 A1 AR 064659A1
Authority
AR
Argentina
Prior art keywords
nanoemulsion
alcohol
composition
surfactant
diseases
Prior art date
Application number
ARP070105827A
Other languages
English (en)
Spanish (es)
Inventor
Roca Montserrat Foguet
Original Assignee
Biofrontera Biosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38042639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064659(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biofrontera Biosciences Gmbh filed Critical Biofrontera Biosciences Gmbh
Publication of AR064659A1 publication Critical patent/AR064659A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP070105827A 2006-12-22 2007-12-21 Nanoemulsion AR064659A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06026698A EP1938801A1 (en) 2006-12-22 2006-12-22 Nanoemulsion

Publications (1)

Publication Number Publication Date
AR064659A1 true AR064659A1 (es) 2009-04-15

Family

ID=38042639

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105827A AR064659A1 (es) 2006-12-22 2007-12-21 Nanoemulsion

Country Status (18)

Country Link
US (2) US11540981B2 (enExample)
EP (2) EP1938801A1 (enExample)
JP (1) JP5558827B2 (enExample)
CN (1) CN101588792B (enExample)
AR (1) AR064659A1 (enExample)
AU (1) AU2007338323B2 (enExample)
BR (1) BRPI0720853A2 (enExample)
CA (1) CA2670715C (enExample)
CL (1) CL2007003730A1 (enExample)
ES (1) ES2602107T3 (enExample)
IL (1) IL198934A (enExample)
MX (1) MX2009006088A (enExample)
NZ (1) NZ577061A (enExample)
RU (1) RU2491917C2 (enExample)
UA (1) UA101471C2 (enExample)
UY (1) UY30833A1 (enExample)
WO (1) WO2008077641A1 (enExample)
ZA (1) ZA200903468B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
EP2494958A1 (en) 2006-12-01 2012-09-05 Anterios, Inc. Amphiphilic Entity Nanoparticles
CA2671133C (en) 2006-12-01 2015-11-24 Anterios, Inc. Peptide nanoparticles and uses therefor
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US10016451B2 (en) 2007-05-31 2018-07-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
JP2010143848A (ja) * 2008-12-18 2010-07-01 Kao Corp 化粧料
CN101874795A (zh) * 2009-04-28 2010-11-03 上海复旦张江生物医药股份有限公司 5-氨基酮戊酸在制备治疗hpv病毒感染的药物的用途
MX336482B (es) * 2009-08-21 2016-01-21 Henk-Andre Kroon Formulaciones vesiculares.
WO2011103510A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha ester emulsions
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
WO2011103514A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha triglyceride emulsions
DE202010004750U1 (de) 2010-04-09 2011-10-11 Biofrontera Bioscience Gmbh Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut
WO2011162818A2 (en) * 2010-06-23 2011-12-29 Controlled Nanovolumes, Inc. Lecithin carrier vesicles and methods of making the same
BRPI1002486B1 (pt) * 2010-07-22 2017-07-18 Evidence Soluções Farmacêuticas Ltda Epp Stabilized topical composition and process of obtaining composition stable topic
JP2012051823A (ja) * 2010-08-31 2012-03-15 Fujifilm Corp 難容性薬物含有水中油型乳化組成物及びその製造方法
EP2617416B1 (en) * 2010-09-14 2015-05-06 Tokyo University of Agriculture Educational Corporation Cancer heat therapy-enhancing agent
US9789123B2 (en) 2010-10-21 2017-10-17 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis
WO2012053007A1 (en) * 2010-10-21 2012-04-26 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment psoriasis
CA2820721C (en) * 2010-12-10 2017-07-11 Ns Technologies Pty Ltd Methods for forming miniemulsions and use thereof for delivering bioactive agents
CN104152530B (zh) 2010-12-24 2017-09-19 爱科来株式会社 癌细胞的检测方法
DE102010056192A1 (de) 2010-12-28 2012-06-28 Gabriele Blume Kolloidales Trägersystem mit penetrierenden Eigenschaften zum Einschließen lipophiler Wirkstoffe und Öle für die topische Anwendung
WO2012103038A2 (en) * 2011-01-24 2012-08-02 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
WO2012103035A1 (en) * 2011-01-24 2012-08-02 Anterios, Inc. Nanoparticle compositions
FR2977801B1 (fr) * 2011-07-11 2013-08-16 Fabre Pierre Dermo Cosmetique Dispositif et procede pour la sterilisation a ultra-haute temperature d'une emulsion, notamment dermo-cosmetique, instable a la temperature de sterilisation
WO2013108254A1 (en) 2012-01-19 2013-07-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Formulation and method for increasing oral bioavailability of drugs
CN102600178A (zh) * 2012-03-08 2012-07-25 西北农林科技大学 一种复方盐酸布替萘芬纳米乳及其制备方法
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
AU2013257546B2 (en) 2012-05-10 2017-12-14 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
GB201208409D0 (en) * 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
JP6112498B2 (ja) * 2012-07-20 2017-04-12 株式会社 Ｍ Ｌａｂｓ 防腐剤・界面活性剤フリーの化粧品原料液、化粧品及び化粧品原料液の調製法
US10137085B2 (en) 2014-03-19 2018-11-27 Nano And Advanced Materials Institute Limited Nanoemulsion for transdermal delivery and method of making the same
EP3129002A4 (en) 2014-04-09 2017-11-08 Nanoceutica Laboratories Pvt. Ltd Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base
WO2016128858A1 (en) * 2015-02-11 2016-08-18 Towhidi Armin Extender for cryopreservation of bovine sperm
WO2016182926A1 (en) * 2015-05-08 2016-11-17 Affinsci Inc. Preparation of nanoemulsions
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
CN107666902B (zh) 2015-05-21 2021-09-21 德玛万科学有限责任公司 局部药物组合物
DK3316857T3 (da) 2015-06-30 2021-10-18 Sequessome Tech Holdings Limited Multifasiske sammensætninger
EP3851161A1 (en) 2015-10-15 2021-07-21 DUSA Pharmaceuticals, Inc. Adjustable illuminator for photodynamic therapy and diagnosis
US10603508B2 (en) 2015-10-15 2020-03-31 Dusa Pharmaceuticals, Inc. Adjustable illuminators and methods for photodynamic therapy and diagnosis
GB201522398D0 (en) * 2015-12-18 2016-02-03 Photocure As Device for photodynamic therapy
CN105997875B (zh) * 2016-07-19 2019-05-21 重庆医科大学 一种明显提高难溶性药物生物利用度的油包水型纳米乳及其制备方法
GB2546128A (en) * 2016-09-28 2017-07-12 Photocure Asa Pharamaceutical compositions comprising hexaminolevulinic acid and methods of using the same
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents
AU2018302103B2 (en) * 2017-07-17 2024-03-07 Sun Pharmaceutical Industries, Inc. Photodynamic therapy method for skin disorders
CN107233303A (zh) * 2017-08-07 2017-10-10 苏州纳美特生物科技有限公司 一种氨基酮戊酸冷霜及其制备方法和应用
TWI719263B (zh) * 2017-10-27 2021-02-21 財團法人國家衛生研究院 用於鼻黏膜之奈米級乳液免疫載劑及其製備方法
US10959975B1 (en) 2017-11-02 2021-03-30 The Tetra Corporation Antifungal composition, method of making composition, and method of using composition
US10357567B1 (en) 2018-01-12 2019-07-23 Dusa Pharmaceuticals, Inc. Methods for photodynamic therapy
CA3099809A1 (en) * 2018-05-11 2019-11-14 Formulytica Pty Ltd Sub-micron emulsions
EP3583954A1 (en) * 2018-06-19 2019-12-25 neubourg skin care GmbH Nanodispersions of birch bark extract, electrospun fibers containing such nanodispersions and their use for the treatment of wounds
WO2020038583A1 (en) 2018-08-23 2020-02-27 Biofrontera Bioscience Gmbh Photodynamic therapy comprising two light exposures at different wavelengths
KR20210049159A (ko) * 2018-08-31 2021-05-04 케민 인더스트리즈, 인코포레이티드 수분산성 인지질 및 리소인지질을 위한 기술
WO2020135600A1 (zh) * 2018-12-28 2020-07-02 南京善思生物科技有限公司 纳米农药制剂及其制备方法
CN110169990A (zh) * 2019-06-19 2019-08-27 苏普丘昆基蒂 牛至油治疗猪腹泻自乳化配方产品及制造工艺
CN114081851A (zh) * 2021-11-01 2022-02-25 苏州纳美特生物科技有限公司 保湿喷雾
CN121001708A (zh) * 2023-04-06 2025-11-21 生物前沿生物科学有限公司 加压纳米乳剂
AU2024253808A1 (en) * 2023-04-06 2025-10-09 Biofrontera Bioscience Gmbh Nanoemulsion without propylene glycol
WO2024208433A1 (en) * 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Nanoemulsion without propylene glycol
WO2024208434A1 (en) * 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Pressurized nanoemulsion

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
MY110708A (en) * 1993-04-14 1999-01-30 Colgate Palmolive Co Microemulsion cleaning composition comprising a glycol mono-alkyl ether
MX9504023A (es) * 1994-09-20 1997-05-31 Johnson & Johnson Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion.
US5780010A (en) 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
SE9503143D0 (sv) * 1995-09-12 1995-09-12 Astra Ab New preparation
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US5895786A (en) * 1996-05-08 1999-04-20 New York Blood Center, Inc. Method for treating viral infections
ATE229282T1 (de) * 1996-09-16 2002-12-15 Nestle Sa Essbare mikroemulsion zum beschichten von nahrungsmitteln, und verwendung zum bräunen und knusprig machen durch mikrowellen
EP0842606B1 (en) 1996-11-13 2000-03-15 The Procter & Gamble Company Disinfecting microemulsions
TWI241915B (en) * 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
US6620437B2 (en) * 1998-07-30 2003-09-16 Colgate-Palmolive Co. Water-in-oil microemulsion for providing cosmetic attributes to fabric softening base composition
DE19852245A1 (de) * 1998-11-12 2000-05-18 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Nanoemulsion
FR2787728B1 (fr) * 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2787703B1 (fr) * 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788449B1 (fr) * 1999-01-14 2001-02-16 Oreal Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2795960B1 (fr) * 1999-07-05 2001-10-19 Sanofi Elf Microemulsions stables pour l'administration d'acides gras a l'homme ou a l'animal, et utilisation de ces microemulsions
US7919113B2 (en) * 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
DE10003620A1 (de) * 2000-01-28 2001-08-02 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Formulierung in nichtwässrigen Lösungsmitteln
US20020155084A1 (en) * 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
US6823387B1 (en) * 2000-06-23 2004-11-23 Microsoft Corporation System and method for enhancing a server's ability to withstand a “SYN flood” denial of service attack
CA2422865C (en) * 2000-08-16 2012-10-16 The General Hospital Corporation D/B/A Massachusetts General Hospital Aminolevulinic acid photodynamic therapy for treating sebaceous gland disorders
JP2002302414A (ja) 2000-12-26 2002-10-18 Kokuriyuudou:Kk スフィンゴ脂質構造物質含有乳化組成物及びその製造方法
JP2006512401A (ja) * 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
US20030148927A1 (en) * 2001-10-05 2003-08-07 Procyte Corporation Stable solutions of peptide copper complexes and cosmetic and pharmaceutical formulations produced therefrom
WO2003061696A2 (en) * 2002-01-23 2003-07-31 Light Sciences Corporation Systems and methods for photodynamic therapy
ES2532906T5 (es) * 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
DK1473367T3 (da) * 2003-04-17 2007-10-01 Affectis Pharmaceuticals Ag Midler og fremgangsmåder til diagnosticering og behandling af effektive lidelser
WO2005027872A2 (en) * 2003-06-04 2005-03-31 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
EP1598060A1 (en) * 2004-05-18 2005-11-23 Nestec S.A. Oil-in-water emulsion for delivery
FR2872038A1 (fr) * 2004-06-23 2005-12-30 Rhodia Chimie Sa Composition cosmetique comprenant un polyorganosiloxane et ses utilisations
TWI365075B (en) * 2004-09-22 2012-06-01 Kao Corp Microemulsion
ATE412400T1 (de) * 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
JP4444149B2 (ja) * 2005-03-30 2010-03-31 株式会社ナリス化粧品 超微細エマルジョンで構成される皮膚外用剤
NZ587597A (en) * 2005-04-28 2011-11-25 Sbi Alapromo Co Ltd Composition comprising 5-aminolevulinic acid or a derivative, iron, and optionally urea, for external treatment of skin
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion

Also Published As

Publication number Publication date
UA101471C2 (en) 2013-04-10
JP5558827B2 (ja) 2014-07-23
EP1938801A1 (en) 2008-07-02
UY30833A1 (es) 2008-07-31
US20230201087A1 (en) 2023-06-29
BRPI0720853A2 (pt) 2014-03-25
CL2007003730A1 (es) 2009-01-23
CN101588792A (zh) 2009-11-25
EP2120872A1 (en) 2009-11-25
US11540981B2 (en) 2023-01-03
IL198934A (en) 2016-04-21
EP2120872B1 (en) 2016-09-21
CN101588792B (zh) 2012-03-21
IL198934A0 (en) 2010-02-17
RU2009128179A (ru) 2011-01-27
AU2007338323A1 (en) 2008-07-03
AU2007338323B2 (en) 2013-07-11
ES2602107T3 (es) 2017-02-17
JP2010513363A (ja) 2010-04-30
ZA200903468B (en) 2010-02-24
MX2009006088A (es) 2009-08-28
CA2670715A1 (en) 2008-07-03
CA2670715C (en) 2015-11-24
WO2008077641A1 (en) 2008-07-03
RU2491917C2 (ru) 2013-09-10
US20090324727A1 (en) 2009-12-31
NZ577061A (en) 2012-01-12

Similar Documents

Publication Publication Date Title
AR064659A1 (es) Nanoemulsion
BRPI0915439B8 (pt) composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição
CU20070203A7 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
CL2013002550A1 (es) Una formulacion farmaceutica inyectable subcutanea liquida estable altamente concentrada de un anticuerpo anti-her2 farmaceuticamente activo que consiste esencialmente de trastuzumab; his/hci un agente estabilizador y un surfactante no ionico; kit y su uso para tratar enfermedades tales como cancer (divisional de solicitud n°0269-2012).
CO6720961A2 (es) Imidazopiridazinas sustituidas
MX2015005328A (es) Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas.
PE20080331A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
DOP2011000188A (es) Compuestos de tiazolopiridinas moduladores de sirtuina
BRPI0925036B8 (pt) uso de trans-t-butil ciclo-hexanol, composição cosmética, medicamento, seus usos e processos para tratar irritação na pele
MX385305B (es) Composiciones de ribósido de nicotinamida para uso tópico en el tratamiento de afecciones de la piel.
BR112014017650A8 (pt) Uso de ésteres de forbol para tratar ou prevenir um ou mais dos sintomas da doença de parkinson
BRPI0512237A (pt) cis-imidazolinas
BRPI0518101A (pt) métodos de produção e sìntese de composições nanoparticuladas, composições obtidas e seu uso
AR062059A1 (es) Espuma farmaceutica con acido graso
NO20083780L (no) Topisk sammensetning omfattende en antibakteriell substans
CR9749A (es) Derivados de xantina como agonistas de hm74a selectivos
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
BR112013003658A2 (pt) compostos antivirais contendo azida
BR112015021124A2 (pt) solução para acne
MX347927B (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
DOP2015000128A (es) Dispersión sólida con solubilidad mejorada que comprende un derivado de tetrazol como ingrediente activo
ECSP088472A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
CL2008001282A1 (es) Composicion farmaceutica con actividad antimicrobiana que comprende un aminoacidos n halogenado y un agente antiinflamatorio; uso para prevenir o tratar una infeccion de tejidos, donde dicho tejido es ocular, nasal, seno nasal o dermico o una infeccion respiratoria.
AR051429A1 (es) Composicion farmaceutica ozonizada y metodos para obtenerla

Legal Events

Date Code Title Description
FC Refusal